- Home
- IMNM vs MLCO Comparison
IMNM vs MLCO Comparison
Compare IMNM & MLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMNM | MLCO |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | 2020 | 2006 |
Fundamental Metrics
Financial Performance| Metric | IMNM | MLCO |
|---|---|---|
| Price | $21.92 | $5.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $32.10 | $9.42 |
| AVG Volume (30 Days) | 1.0M | ★ 2.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.06 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,041,000.00 | N/A |
| Revenue This Year | N/A | $4.80 |
| Revenue Next Year | $11.53 | $4.40 |
| P/E Ratio | ★ N/A | $12.16 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.15 | $4.55 |
| 52 Week High | $27.65 | $10.15 |
Technical Indicators
Market Signals| Indicator | IMNM | MLCO |
|---|---|---|
| Relative Strength Index (RSI) | 43.67 | 43.97 |
| Support Level | $18.98 | $5.88 |
| Resistance Level | $22.57 | $6.54 |
| Average True Range (ATR) | 1.18 | 0.31 |
| MACD | -0.31 | 0.06 |
| Stochastic Oscillator | 15.51 | 54.40 |
Price Performance
Historical ComparisonAbout IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
About MLCO Melco Resorts & Entertainment Limited
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 81% from Macao, with the rest largely from the Philippines as of 2024.